The Billion-Dollar Biodiversity Fund That Collected Pennies

When global summits set up ambitious financial instruments, the gap between bureaucratic grandiosity and real-world economics rarely remains hidden for long. The Cali Fund, created under the umbrella of the UN Convention on Biological Diversity, promised to extract $1 billion annually from corporations tapping into natural genetic data. Eighteen months after its launch in early 2025, as delegates gather for the Cop17 summit in Yerevan, the grand fund has collected a total of $7,085 in deposited cash.

The stark arithmetic of this initiative exposes the fundamental flaws of international committee work. While organizers envisioned a steady stream of revenue from global pharmaceutical giants—suggesting voluntary contributions of 1 percent of profits or 0.1 percent of total revenue—the actual donor roll consists of precisely three small European firms. Prozomix, TierraViva AI, and E-Biom contributed tiny sums, while the world's largest pharmaceutical manufacturers have not paid a single cent.

Campaigners and committee members predictably accuse the industry of exploiting biological data without paying for its upkeep. A study by Zero Carbon Analytics highlighted that the top 15 pharmaceutical firms earned roughly $161 billion in profits in 2025, arguing that their combined contribution could have reached $756 million under the suggested formula. Yet expecting private capital to voluntarily subsidize broad UN targets ignores basic market mechanics and legal clarity.

The industry’s pushback reveals why top-down administrative schemes repeatedly founder. Representatives from the International Federation of Pharmaceutical Manufacturers and Associations pointed out that the Cali Fund imposes arbitrary levies regardless of whether a drug actually relies on digital sequence information. The fund overlaps with existing national frameworks, creates double taxation risks, and relies on fundamentally flawed assumptions about how modern biotechnological research functions.

Equally revealing is the internal machinery of global environmental governance. Environmental advocates themselves note that international bodies have spent considerably more money on administrative meetings and global travel discussing the Cali Fund than the scheme currently holds in its accounts. UN spokespeople insist that financial mechanisms require several years to establish operational infrastructure before contributions scale up. In practice, however, building another costly administrative apparatus to manage pennies simply highlights the institutional self-preservation driving such international initiatives.

Major drugmakers like Sanofi and GSK maintain that open access to genetic sequence databases remains essential for medical development and rapid public health responses. They have declined to pledge voluntary funding until global bodies clarify how this mechanism will function alongside existing national laws. Until international bureaucracies learn to design realistic, targeted, and accountable policy tools rather than broad-brush funding demands, private industry will continue to keep its checkbooks closed.

Written by Martina Kirchner martina.kirchner@alpineweekly.com